Alexandria Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $23.1M | Sell |
122,216
-3,473
| -3% | -$656K | 2.14% | 4 |
|
|
2021
Q2 | $21.3M | Sell |
125,689
-1,742
| -1% | -$295K | 1.98% | 4 |
|
|
2021
Q1 | $18M | Sell |
127,431
-867
| -0.7% | -$122K | 1.82% | 7 |
|
|
2020
Q4 | $16.7M | Sell |
128,298
-2,436
| -2% | -$317K | 1.77% | 6 |
|
|
2020
Q3 | $18.6M | Sell |
130,734
-1,083
| -0.8% | -$154K | 2.22% | 4 |
|
|
2020
Q2 | $19.5M | Sell |
131,817
-10,637
| -7% | -$1.58M | 2.53% | 4 |
|
|
2020
Q1 | $15.5M | Sell |
142,454
-6,983
| -5% | -$760K | 2.54% | 4 |
|
|
2019
Q4 | $17.2M | Buy |
149,437
+739
| +0.5% | +$85.1K | 2.3% | 5 |
|
|
2019
Q3 | $12M | Buy |
148,698
+8,182
| +6% | +$658K | 1.77% | 7 |
|
|
2019
Q2 | $10.2M | Buy |
140,516
+327
| +0.2% | +$23.7K | 1.45% | 12 |
|
|
2019
Q1 | $13.1M | Sell |
140,189
-295
| -0.2% | -$27.6K | 1.9% | 6 |
|
|
2018
Q4 | $10.2M | Sell |
140,484
-342
| -0.2% | -$24.9K | 1.66% | 9 |
|
|
2018
Q3 | $12.3M | Buy |
140,826
+224
| +0.2% | +$19.6K | 1.81% | 8 |
|
|
2018
Q2 | $13.8M | Sell |
140,602
-239
| -0.2% | -$23.5K | 2.08% | 7 |
|
|
2018
Q1 | $16.8M | Sell |
140,841
-5,576
| -4% | -$664K | 2.49% | 3 |
|
|
2017
Q4 | $18.6M | Buy |
+146,417
| New | +$18.6M | 2.71% | 3 |
|